View Future GrowthThis company is no longer activeThe company may no longer be operating, as it may be out of business. Find out why through their latest events.See Latest EventsPLx Pharma Winddown 과거 순이익 실적과거 기준 점검 0/6PLx Pharma Winddown 의 수입은 연평균 -29.5%의 비율로 감소해 온 반면, Pharmaceuticals 산업은 연평균 8.8%의 비율로 증가했습니다. 매출은 연평균 63.3%의 비율로 증가해 왔습니다.핵심 정보-29.50%순이익 성장률-2.77%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률7.33%매출 성장률63.26%자기자본이익률-104.74%순이익률-606.91%최근 순이익 업데이트30 Sep 2022최근 과거 실적 업데이트공시 • Oct 27PLx Pharma Inc. to Report Q3, 2022 Results on Nov 11, 2022PLx Pharma Inc. announced that they will report Q3, 2022 results at 9:30 AM, US Eastern Standard Time on Nov 11, 2022공시 • Jul 28PLx Pharma Inc. to Report Q2, 2022 Results on Aug 12, 2022PLx Pharma Inc. announced that they will report Q2, 2022 results Pre-Market on Aug 12, 2022공시 • Apr 23PLx Pharma Inc. to Report Q1, 2022 Results on May 13, 2022PLx Pharma Inc. announced that they will report Q1, 2022 results Pre-Market on May 13, 2022공시 • Feb 24PLx Pharma Inc. to Report Q4, 2021 Results on Mar 11, 2022PLx Pharma Inc. announced that they will report Q4, 2021 results Pre-Market on Mar 11, 2022공시 • Nov 05PLx Pharma Inc. to Report Q3, 2020 Results on Nov 13, 2020PLx Pharma Inc. announced that they will report Q3, 2020 results on Nov 13, 2020공시 • Aug 07PLx Pharma Inc. to Report Q2, 2020 Results on Aug 14, 2020PLx Pharma Inc. announced that they will report Q2, 2020 results at 9:00 AM, Eastern Standard Time on Aug 14, 2020모든 업데이트 보기Recent updates공시 • Oct 19PLx Pharma Winddown Corp. Files Form 15PLx Pharma Winddown Corp. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock under the Securities Exchange Act of 1934, as amended. The par value of the company's common stock was $0.001 per share.공시 • Jul 10Plx Pharma Winddown Corp. Announces Executive ChangesPLx Pharma Winddown Corp. on June 30, 2023, the Company terminated the employment of Natasha Giordano, President, and of Rita O’Connor, Head of Manufacturing and Supply Chain. Effective as of July 1, 2023, Ms. O’Connor entered into a consulting arrangement with the Company.Board Change • May 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Member of Scientific Advisory Board Makis Deliargyris was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.공시 • Feb 14PLx Pharma Receives Written Notice from the Listing Qualifications Department of The Nasdaq Stock Market LLCOn February 7, 2023, PLx Pharma Inc. received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC regarding its noncompliance with Nasdaq Listing Rule 5605(c)(2), which requires, among other things, that the Audit Committee (the Audit Committee") of the Board of Directors of the Company (the Board") be comprised of a minimum of three independent directors. As previously disclosed, John W. Hadden II ceased serving on the Board and its committees as of January 19, 2023, and as a result, the Company's Audit Committee is currently comprised of only two independent directors resulting in the noncompliance. In accordance with Nasdaq Listing Rule 5605(c)(4), the Company is granted a cure period in order to regain compliance with Nasdaq Listing Rule 5605 lasting until the earlier of the Company's next annual stockholders' meeting or January 19, 2024 or, if the next annual stockholders' meeting is held before July 18, 2023, then no later than July 18, 2023. The Company's common stock will continue to be listed and traded on the Nasdaq Capital Market during the compliance period, subject to the Company's compliance with the other continued listing requirements of the Nasdaq Capital Market.공시 • Jan 22PLx Pharma Inc. Announces Resignation of John W. Hadden II as Member of BoardOn January 19, 2023, John W. Hadden II, a member of the Board of Directors of PLx Pharma Inc., resigned from the Board effective immediately. Mr. Hadden's resignation is not the result of any disagreement with the Company.공시 • Oct 27PLx Pharma Inc. to Report Q3, 2022 Results on Nov 11, 2022PLx Pharma Inc. announced that they will report Q3, 2022 results at 9:30 AM, US Eastern Standard Time on Nov 11, 2022공시 • Oct 10PLx Pharma Receives Written Notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC Regarding Minimum Bid Price RequirementOn October 3, 2022, PLx Pharma Inc. ("the Company") received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying it that, for a period of 30 consecutive business days, the bid price of its common stock closed below the minimum of $1.00 per share required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days, or until April 3, 2023, to regain compliance with the minimum bid price requirement. If, at any time during the 180-day compliance period, the closing bid price of the Company's common stock is at least $1.00 per share for a minimum of 10 consecutive business days, the Company will have regained compliance, and Nasdaq will provide the Company with written confirmation of such. If Company fails to regain compliance before April 3, 2023, but meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, the Company may be eligible for additional time to regain compliance with the minimum bid price requirement.공시 • Sep 30PLx Pharma Inc., Annual General Meeting, Nov 08, 2022PLx Pharma Inc., Annual General Meeting, Nov 08, 2022, at 09:00 US Eastern Standard Time. Agenda: To elect each of Gary S. Balkema, Kirk Calhoun, Robert Casale, John W. Hadden II, Michael J. Valentino and Natasha Giordano, to serve as directors until the company’s 2023 Annual Meeting of Stockholders and until their successors are duly elected and qualify; to consider an advisory vote on the compensation of company named executive officers as disclosed in the proxy statement; to ratify the appointment of Marcum LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2022; and to transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.공시 • Jul 28PLx Pharma Inc. to Report Q2, 2022 Results on Aug 12, 2022PLx Pharma Inc. announced that they will report Q2, 2022 results Pre-Market on Aug 12, 2022공시 • Apr 23PLx Pharma Inc. to Report Q1, 2022 Results on May 13, 2022PLx Pharma Inc. announced that they will report Q1, 2022 results Pre-Market on May 13, 2022Recent Insider Transactions • Mar 24Key Executive recently bought €46k worth of stockOn the 15th of March, Rita O'Connor bought around 14k shares on-market at roughly €3.34 per share. This was the largest purchase by an insider in the last 3 months. This was Rita's only on-market trade for the last 12 months.Recent Insider Transactions • Mar 21Key Executive recently bought €46k worth of stockOn the 15th of March, Rita O'Connor bought around 14k shares on-market at roughly €3.34 per share. This was the largest purchase by an insider in the last 3 months. This was Rita's only on-market trade for the last 12 months.Breakeven Date Change • Mar 12No longer forecast to breakevenThe 3 analysts covering PLx Pharma no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$6.50m in 2024. New consensus forecast suggests the company will make a loss of US$21.4m in 2024.공시 • Feb 24PLx Pharma Inc. to Report Q4, 2021 Results on Mar 11, 2022PLx Pharma Inc. announced that they will report Q4, 2021 results Pre-Market on Mar 11, 2022공시 • Aug 04PLx Pharma Inc.’s VAZALORE to Launch in Nearly 8,000 CVS Stores this MonthPLx Pharma Inc. announced that three stock-keeping units (“SKUs”) of VAZALORE, the first and only U.S. Food and Drug Administration (“FDA”) approved liquid-filled aspirin capsules, will be available in nearly 8,000 CVS stores later this month. CVS, a leading health solutions company, is preparing its retail space with ‘Coming Soon’ placeholders and shelf trays in many of its stores. This includes all three SKUs: VAZALORE 81 mg, 12 count; VAZALORE 81 mg, 30 count; and VAZALORE 325 mg, 30 count. About VAZALORE: VAZALORE is an FDA-approved liquid-filled aspirin capsule that provides patients with vascular disease and diabetic patients who are candidates for aspirin therapy based on physician recommendation, with fast, reliable and predictable platelet inhibition as compared to enteric-coated aspirin. It also reduces the risk of stomach erosions and ulcers, as compared to immediate-release aspirin, common in an acute setting.공시 • Jul 20PLx Pharma Inc.’s VAZALORE to Launch in over 8,000 Walgreens Stores Nationwide in AugustPLx Pharma Inc. announced that three stock-keeping units (“SKUs”) of VAZALORE, the first and only U.S. Food and Drug Administration (“FDA”) approved liquid-filled aspirin capsules, will be available in over 8,000 Walgreens stores nationwide later in August. Walgreens has already inserted placeholders to reserve space on shelves for all three SKUs: VAZALORE 81 mg, 12 count; VAZALORE 81 mg, 30 count; and VAZALORE 325 mg, 30 count. VAZALORE is an FDA-approved liquid-filled aspirin capsule that provides patients with vascular disease and diabetic patients who are candidates for aspirin therapy based on physician recommendation, with fast, reliable and predictable platelet inhibition as compared to enteric-coated aspirin. It also reduces the risk of stomach erosions and ulcers, as compared to immediate-release aspirin, common in an acute setting.공시 • Jul 15Plx Pharma Inc.’s VAZALORE to Launch in over 4,500 Walmart Stores Nationwide in AugustPLx Pharma Inc. announced that three stock-keeping units (“SKUs”) of VAZALORE, the first and only U.S. Food and Drug Administration (“FDA”) approved liquid-filled aspirin capsules, will be available in over 4,500 Walmart stores across the United States in mid-August. The three SKUs include: VAZALORE 81 mg, 12 count; VAZALORE 81 mg, 30 count; and VAZALORE 325 mg, 30 count.Recent Insider Transactions • Jun 17Executive Chairman recently bought €82k worth of stockOn the 14th of June, Michael Valentino bought around 8k shares on-market at roughly €10.30 per share. This was the largest purchase by an insider in the last 3 months. Michael has been a buyer over the last 12 months, purchasing a net total of €250k worth in shares.Analyst Estimate Surprise Post Earnings • Mar 13Revenue in line with expectationsRevenue was in line with analyst estimates. Over the next year, revenue is expected to shrink by 100% compared to a 3.1% growth forecast for the Pharmaceuticals industry in Germany.Recent Insider Transactions • Mar 10Executive Chairman recently bought €168k worth of stockOn the 5th of March, Michael Valentino bought around 25k shares on-market at roughly €6.72 per share. This was the largest purchase by an insider in the last 3 months. This was Michael's only on-market trade for the last 12 months.공시 • Mar 05+ 1 more updatePLx Pharma Inc. has completed a Follow-on Equity Offering in the amount of $63 million.PLx Pharma Inc. has completed a Follow-on Equity Offering in the amount of $63 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 7,875,000 Price\Range: $8 Discount Per Security: $0.48공시 • Mar 04PLx Pharma Inc. has completed a Follow-on Equity Offering in the amount of $2.3 million.PLx Pharma Inc. has completed a Follow-on Equity Offering in the amount of $2.3 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering공시 • Mar 03PLx Pharma Receives FDA Approval of sNDAs for Both Vazalore 325 Mg and 81 MgPLx Pharma Inc. announced that the U.S. Food and Drug Administration (“FDA”) approved supplemental new drug applications (“sNDAs”) for its lead products, VAZALORE™ 325 mg and VAZALORE™ 81 mg (referred to together as “VAZALORE”), the first ever novel, liquid-filled aspirin capsule. In October 2020, the company submitted separate supplemental new drug applications (“sNDAs”) for each dose strength. The submissions were considered chemistry and manufacturing control (“CMC”) filings as they included information on a change in formulation and the new manufacturing site for VAZALORE 325 mg and a new product strength for the 81 mg dose. The submission for the 325 mg dose also contained the results of a clinical study, demonstrating VAZALORE's bioequivalence to immediate-release aspirin, further supporting the change in formulation. The submission for the 81 mg dose builds off the information in the original approved new drug application, as well as the recent sNDA submitted for VAZALORE 325 mg.Is New 90 Day High Low • Feb 11New 90-day high: €6.05The company is up 91% from its price of €3.16 on 13 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 11% over the same period.Is New 90 Day High Low • Dec 23New 90-day high: €5.20The company is up 82% from its price of €2.86 on 24 September 2020. The German market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.공시 • Dec 01PLx Pharma Inc. announced that it has received $18.008598 million in funding from White Rock Capital Management, L.P., Level One Partners LLC and other investorsOn November 30, 2020, PLx Pharma Inc. (NasdaqCM:PLXP) closed the transaction. The transaction included participation from 25 investors.공시 • Nov 18PLx Pharma Inc. Submits Supplemental New Drug Applications for VAZALORE™ 325 mg and 81 mg to U.S. Food and Drug AdministrationPLx Pharma Inc. announced that two chemistry and manufacturing control (‘CMC’) supplemental New Drug Applications (‘sNDAs’), one for VAZALORE 325 mg and one for VAZALORE 81 mg dose (referred to together as ‘VAZALORE’), were submitted to the U.S. Food and Drug Administration (‘FDA’) in October for regulatory approval. The 325 mg sNDA provided information on a change in formulation and a new manufacturing site for the currently approved VAZALORE and also contains a bioequivalence (‘BE’) clinical study report with the required data and analyses from the recently completed BE study. The submission for the 81 mg dose provided for a new product strength of VAZALORE and builds off the information in the original approved NDA (New Drug Application) and the recent sNDA submitted for VAZALORE 325 mg. The Company received acknowledgement letters from the FDA, officially confirming the receipt of the submissions and setting the estimated completion date for its reviews for VAZALORE 325 mg and VAZALORE 81 mg for the end of February 2021. If approved, the Company plans to bring both doses of VAZALORE to market in the third quarter of 2021. VAZALORE 325 mg is an FDA-approved liquid-filled aspirin capsule that provides patients with vascular disease and diabetic patients who are candidates for aspirin therapy with faster, reliable and more predictable platelet inhibition as compared to enteric-coated aspirin, while also reducing the risk of stomach erosions and ulcers, as compared to immediate-release aspirin, common in an acute setting. PLx’s supplemental New Drug Applications for VAZALORE 325 mg and VAZALORE 81 mg dose strengths, submitted in October 2020 to the U.S. Food and Drug Administration, are currently under regulatory review.공시 • Nov 17PLx Pharma Inc. announced that it expects to receive $18.008598 million in funding from White Rock Capital Management, L.P., Level One Partners LLC and other investorsPLx Pharma Inc. (NasdaqCM:PLXP) announced that it has entered into a securities purchase agreement with certain institutional and accredited investors co-led by new investors White Rock Capital Management, L.P. and Level One Partners LLC for private placement of 4,755,373 immediately separable units at a price of $3.787 per unit for gross proceeds of $18,008,597.551 on November 16, 2020. Each unit consists of one common share and 1.1 common share warrant. Each warrant is exercisable at $4.31 per share for a period of 5 years from issuance. The transaction is expected to close on or about November 18, 2020, subject to satisfaction of customary closing conditions. The securities are issued pursuant to exemption provided under Section 4(a)(2) of the Securities Act and Rule 506 of Registration D.Is New 90 Day High Low • Nov 16New 90-day high: €3.58The company is up 27% from its price of €2.82 on 18 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Analyst Estimate Surprise Post Earnings • Nov 15Revenue in line with expectationsRevenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 1,828%, compared to a 2.8% growth forecast for the Pharmaceuticals industry in Germany.공시 • Nov 05PLx Pharma Inc. to Report Q3, 2020 Results on Nov 13, 2020PLx Pharma Inc. announced that they will report Q3, 2020 results on Nov 13, 2020공시 • Aug 07PLx Pharma Inc. to Report Q2, 2020 Results on Aug 14, 2020PLx Pharma Inc. announced that they will report Q2, 2020 results at 9:00 AM, Eastern Standard Time on Aug 14, 2020공시 • Jul 02PLx Pharma Inc.(NasdaqCM:PLXP) dropped from Russell Microcap Value IndexPLx Pharma Inc.(NasdaqCM:PLXP) dropped from Russell Microcap Value Index매출 및 비용 세부 내역PLx Pharma Winddown가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이DB:1D5A 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비30 Sep 225-2862330 Jun 2211-4164331 Mar 2210-4856431 Dec 218-4940430 Sep 217-6122530 Jun 210-4313431 Mar 210-309531 Dec 200-179430 Sep 200-1110430 Jun 200-610431 Mar 200-1010431 Dec 191-3410530 Sep 191-299530 Jun 191-348531 Mar 191-288431 Dec 18118430 Sep 181-108530 Jun 181-109531 Mar 181-911531 Dec 171-1510430 Sep 170-910230 Jun 170-68131 Mar 170-55031 Dec 160-55030 Sep 160-44030 Jun 160-53031 Mar 160-42031 Dec 150-42030 Sep 150-42130 Jun 150-32131 Mar 150-42231 Dec 140-52331 Dec 131-946양질의 수익: 1D5A 은(는) 현재 수익성이 없습니다.이익 마진 증가: 1D5A는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 1D5A은 수익성이 없으며 지난 5년 동안 손실이 연평균 29.5% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 1D5A의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: 1D5A은 수익성이 없어 지난 해 수익 성장률을 Pharmaceuticals 업계(16.1%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: 1D5A는 현재 수익성이 없으므로 자본 수익률이 음수(-104.74%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2023/08/19 05:14종가2023/05/22 00:00수익2022/09/30연간 수익2021/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스PLx Pharma Winddown Corp.는 6명의 분석가가 다루고 있습니다. 이 중 명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Kenneth TrbovichBrean Capital Historical (Janney Montgomery)Hamed KhorsandBWS Financial Inc.Jason ButlerCitizens JMP Securities, LLC3명의 분석가 더 보기
공시 • Oct 27PLx Pharma Inc. to Report Q3, 2022 Results on Nov 11, 2022PLx Pharma Inc. announced that they will report Q3, 2022 results at 9:30 AM, US Eastern Standard Time on Nov 11, 2022
공시 • Jul 28PLx Pharma Inc. to Report Q2, 2022 Results on Aug 12, 2022PLx Pharma Inc. announced that they will report Q2, 2022 results Pre-Market on Aug 12, 2022
공시 • Apr 23PLx Pharma Inc. to Report Q1, 2022 Results on May 13, 2022PLx Pharma Inc. announced that they will report Q1, 2022 results Pre-Market on May 13, 2022
공시 • Feb 24PLx Pharma Inc. to Report Q4, 2021 Results on Mar 11, 2022PLx Pharma Inc. announced that they will report Q4, 2021 results Pre-Market on Mar 11, 2022
공시 • Nov 05PLx Pharma Inc. to Report Q3, 2020 Results on Nov 13, 2020PLx Pharma Inc. announced that they will report Q3, 2020 results on Nov 13, 2020
공시 • Aug 07PLx Pharma Inc. to Report Q2, 2020 Results on Aug 14, 2020PLx Pharma Inc. announced that they will report Q2, 2020 results at 9:00 AM, Eastern Standard Time on Aug 14, 2020
공시 • Oct 19PLx Pharma Winddown Corp. Files Form 15PLx Pharma Winddown Corp. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock under the Securities Exchange Act of 1934, as amended. The par value of the company's common stock was $0.001 per share.
공시 • Jul 10Plx Pharma Winddown Corp. Announces Executive ChangesPLx Pharma Winddown Corp. on June 30, 2023, the Company terminated the employment of Natasha Giordano, President, and of Rita O’Connor, Head of Manufacturing and Supply Chain. Effective as of July 1, 2023, Ms. O’Connor entered into a consulting arrangement with the Company.
Board Change • May 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Member of Scientific Advisory Board Makis Deliargyris was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
공시 • Feb 14PLx Pharma Receives Written Notice from the Listing Qualifications Department of The Nasdaq Stock Market LLCOn February 7, 2023, PLx Pharma Inc. received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC regarding its noncompliance with Nasdaq Listing Rule 5605(c)(2), which requires, among other things, that the Audit Committee (the Audit Committee") of the Board of Directors of the Company (the Board") be comprised of a minimum of three independent directors. As previously disclosed, John W. Hadden II ceased serving on the Board and its committees as of January 19, 2023, and as a result, the Company's Audit Committee is currently comprised of only two independent directors resulting in the noncompliance. In accordance with Nasdaq Listing Rule 5605(c)(4), the Company is granted a cure period in order to regain compliance with Nasdaq Listing Rule 5605 lasting until the earlier of the Company's next annual stockholders' meeting or January 19, 2024 or, if the next annual stockholders' meeting is held before July 18, 2023, then no later than July 18, 2023. The Company's common stock will continue to be listed and traded on the Nasdaq Capital Market during the compliance period, subject to the Company's compliance with the other continued listing requirements of the Nasdaq Capital Market.
공시 • Jan 22PLx Pharma Inc. Announces Resignation of John W. Hadden II as Member of BoardOn January 19, 2023, John W. Hadden II, a member of the Board of Directors of PLx Pharma Inc., resigned from the Board effective immediately. Mr. Hadden's resignation is not the result of any disagreement with the Company.
공시 • Oct 27PLx Pharma Inc. to Report Q3, 2022 Results on Nov 11, 2022PLx Pharma Inc. announced that they will report Q3, 2022 results at 9:30 AM, US Eastern Standard Time on Nov 11, 2022
공시 • Oct 10PLx Pharma Receives Written Notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC Regarding Minimum Bid Price RequirementOn October 3, 2022, PLx Pharma Inc. ("the Company") received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying it that, for a period of 30 consecutive business days, the bid price of its common stock closed below the minimum of $1.00 per share required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days, or until April 3, 2023, to regain compliance with the minimum bid price requirement. If, at any time during the 180-day compliance period, the closing bid price of the Company's common stock is at least $1.00 per share for a minimum of 10 consecutive business days, the Company will have regained compliance, and Nasdaq will provide the Company with written confirmation of such. If Company fails to regain compliance before April 3, 2023, but meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, the Company may be eligible for additional time to regain compliance with the minimum bid price requirement.
공시 • Sep 30PLx Pharma Inc., Annual General Meeting, Nov 08, 2022PLx Pharma Inc., Annual General Meeting, Nov 08, 2022, at 09:00 US Eastern Standard Time. Agenda: To elect each of Gary S. Balkema, Kirk Calhoun, Robert Casale, John W. Hadden II, Michael J. Valentino and Natasha Giordano, to serve as directors until the company’s 2023 Annual Meeting of Stockholders and until their successors are duly elected and qualify; to consider an advisory vote on the compensation of company named executive officers as disclosed in the proxy statement; to ratify the appointment of Marcum LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2022; and to transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
공시 • Jul 28PLx Pharma Inc. to Report Q2, 2022 Results on Aug 12, 2022PLx Pharma Inc. announced that they will report Q2, 2022 results Pre-Market on Aug 12, 2022
공시 • Apr 23PLx Pharma Inc. to Report Q1, 2022 Results on May 13, 2022PLx Pharma Inc. announced that they will report Q1, 2022 results Pre-Market on May 13, 2022
Recent Insider Transactions • Mar 24Key Executive recently bought €46k worth of stockOn the 15th of March, Rita O'Connor bought around 14k shares on-market at roughly €3.34 per share. This was the largest purchase by an insider in the last 3 months. This was Rita's only on-market trade for the last 12 months.
Recent Insider Transactions • Mar 21Key Executive recently bought €46k worth of stockOn the 15th of March, Rita O'Connor bought around 14k shares on-market at roughly €3.34 per share. This was the largest purchase by an insider in the last 3 months. This was Rita's only on-market trade for the last 12 months.
Breakeven Date Change • Mar 12No longer forecast to breakevenThe 3 analysts covering PLx Pharma no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$6.50m in 2024. New consensus forecast suggests the company will make a loss of US$21.4m in 2024.
공시 • Feb 24PLx Pharma Inc. to Report Q4, 2021 Results on Mar 11, 2022PLx Pharma Inc. announced that they will report Q4, 2021 results Pre-Market on Mar 11, 2022
공시 • Aug 04PLx Pharma Inc.’s VAZALORE to Launch in Nearly 8,000 CVS Stores this MonthPLx Pharma Inc. announced that three stock-keeping units (“SKUs”) of VAZALORE, the first and only U.S. Food and Drug Administration (“FDA”) approved liquid-filled aspirin capsules, will be available in nearly 8,000 CVS stores later this month. CVS, a leading health solutions company, is preparing its retail space with ‘Coming Soon’ placeholders and shelf trays in many of its stores. This includes all three SKUs: VAZALORE 81 mg, 12 count; VAZALORE 81 mg, 30 count; and VAZALORE 325 mg, 30 count. About VAZALORE: VAZALORE is an FDA-approved liquid-filled aspirin capsule that provides patients with vascular disease and diabetic patients who are candidates for aspirin therapy based on physician recommendation, with fast, reliable and predictable platelet inhibition as compared to enteric-coated aspirin. It also reduces the risk of stomach erosions and ulcers, as compared to immediate-release aspirin, common in an acute setting.
공시 • Jul 20PLx Pharma Inc.’s VAZALORE to Launch in over 8,000 Walgreens Stores Nationwide in AugustPLx Pharma Inc. announced that three stock-keeping units (“SKUs”) of VAZALORE, the first and only U.S. Food and Drug Administration (“FDA”) approved liquid-filled aspirin capsules, will be available in over 8,000 Walgreens stores nationwide later in August. Walgreens has already inserted placeholders to reserve space on shelves for all three SKUs: VAZALORE 81 mg, 12 count; VAZALORE 81 mg, 30 count; and VAZALORE 325 mg, 30 count. VAZALORE is an FDA-approved liquid-filled aspirin capsule that provides patients with vascular disease and diabetic patients who are candidates for aspirin therapy based on physician recommendation, with fast, reliable and predictable platelet inhibition as compared to enteric-coated aspirin. It also reduces the risk of stomach erosions and ulcers, as compared to immediate-release aspirin, common in an acute setting.
공시 • Jul 15Plx Pharma Inc.’s VAZALORE to Launch in over 4,500 Walmart Stores Nationwide in AugustPLx Pharma Inc. announced that three stock-keeping units (“SKUs”) of VAZALORE, the first and only U.S. Food and Drug Administration (“FDA”) approved liquid-filled aspirin capsules, will be available in over 4,500 Walmart stores across the United States in mid-August. The three SKUs include: VAZALORE 81 mg, 12 count; VAZALORE 81 mg, 30 count; and VAZALORE 325 mg, 30 count.
Recent Insider Transactions • Jun 17Executive Chairman recently bought €82k worth of stockOn the 14th of June, Michael Valentino bought around 8k shares on-market at roughly €10.30 per share. This was the largest purchase by an insider in the last 3 months. Michael has been a buyer over the last 12 months, purchasing a net total of €250k worth in shares.
Analyst Estimate Surprise Post Earnings • Mar 13Revenue in line with expectationsRevenue was in line with analyst estimates. Over the next year, revenue is expected to shrink by 100% compared to a 3.1% growth forecast for the Pharmaceuticals industry in Germany.
Recent Insider Transactions • Mar 10Executive Chairman recently bought €168k worth of stockOn the 5th of March, Michael Valentino bought around 25k shares on-market at roughly €6.72 per share. This was the largest purchase by an insider in the last 3 months. This was Michael's only on-market trade for the last 12 months.
공시 • Mar 05+ 1 more updatePLx Pharma Inc. has completed a Follow-on Equity Offering in the amount of $63 million.PLx Pharma Inc. has completed a Follow-on Equity Offering in the amount of $63 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 7,875,000 Price\Range: $8 Discount Per Security: $0.48
공시 • Mar 04PLx Pharma Inc. has completed a Follow-on Equity Offering in the amount of $2.3 million.PLx Pharma Inc. has completed a Follow-on Equity Offering in the amount of $2.3 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering
공시 • Mar 03PLx Pharma Receives FDA Approval of sNDAs for Both Vazalore 325 Mg and 81 MgPLx Pharma Inc. announced that the U.S. Food and Drug Administration (“FDA”) approved supplemental new drug applications (“sNDAs”) for its lead products, VAZALORE™ 325 mg and VAZALORE™ 81 mg (referred to together as “VAZALORE”), the first ever novel, liquid-filled aspirin capsule. In October 2020, the company submitted separate supplemental new drug applications (“sNDAs”) for each dose strength. The submissions were considered chemistry and manufacturing control (“CMC”) filings as they included information on a change in formulation and the new manufacturing site for VAZALORE 325 mg and a new product strength for the 81 mg dose. The submission for the 325 mg dose also contained the results of a clinical study, demonstrating VAZALORE's bioequivalence to immediate-release aspirin, further supporting the change in formulation. The submission for the 81 mg dose builds off the information in the original approved new drug application, as well as the recent sNDA submitted for VAZALORE 325 mg.
Is New 90 Day High Low • Feb 11New 90-day high: €6.05The company is up 91% from its price of €3.16 on 13 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 11% over the same period.
Is New 90 Day High Low • Dec 23New 90-day high: €5.20The company is up 82% from its price of €2.86 on 24 September 2020. The German market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
공시 • Dec 01PLx Pharma Inc. announced that it has received $18.008598 million in funding from White Rock Capital Management, L.P., Level One Partners LLC and other investorsOn November 30, 2020, PLx Pharma Inc. (NasdaqCM:PLXP) closed the transaction. The transaction included participation from 25 investors.
공시 • Nov 18PLx Pharma Inc. Submits Supplemental New Drug Applications for VAZALORE™ 325 mg and 81 mg to U.S. Food and Drug AdministrationPLx Pharma Inc. announced that two chemistry and manufacturing control (‘CMC’) supplemental New Drug Applications (‘sNDAs’), one for VAZALORE 325 mg and one for VAZALORE 81 mg dose (referred to together as ‘VAZALORE’), were submitted to the U.S. Food and Drug Administration (‘FDA’) in October for regulatory approval. The 325 mg sNDA provided information on a change in formulation and a new manufacturing site for the currently approved VAZALORE and also contains a bioequivalence (‘BE’) clinical study report with the required data and analyses from the recently completed BE study. The submission for the 81 mg dose provided for a new product strength of VAZALORE and builds off the information in the original approved NDA (New Drug Application) and the recent sNDA submitted for VAZALORE 325 mg. The Company received acknowledgement letters from the FDA, officially confirming the receipt of the submissions and setting the estimated completion date for its reviews for VAZALORE 325 mg and VAZALORE 81 mg for the end of February 2021. If approved, the Company plans to bring both doses of VAZALORE to market in the third quarter of 2021. VAZALORE 325 mg is an FDA-approved liquid-filled aspirin capsule that provides patients with vascular disease and diabetic patients who are candidates for aspirin therapy with faster, reliable and more predictable platelet inhibition as compared to enteric-coated aspirin, while also reducing the risk of stomach erosions and ulcers, as compared to immediate-release aspirin, common in an acute setting. PLx’s supplemental New Drug Applications for VAZALORE 325 mg and VAZALORE 81 mg dose strengths, submitted in October 2020 to the U.S. Food and Drug Administration, are currently under regulatory review.
공시 • Nov 17PLx Pharma Inc. announced that it expects to receive $18.008598 million in funding from White Rock Capital Management, L.P., Level One Partners LLC and other investorsPLx Pharma Inc. (NasdaqCM:PLXP) announced that it has entered into a securities purchase agreement with certain institutional and accredited investors co-led by new investors White Rock Capital Management, L.P. and Level One Partners LLC for private placement of 4,755,373 immediately separable units at a price of $3.787 per unit for gross proceeds of $18,008,597.551 on November 16, 2020. Each unit consists of one common share and 1.1 common share warrant. Each warrant is exercisable at $4.31 per share for a period of 5 years from issuance. The transaction is expected to close on or about November 18, 2020, subject to satisfaction of customary closing conditions. The securities are issued pursuant to exemption provided under Section 4(a)(2) of the Securities Act and Rule 506 of Registration D.
Is New 90 Day High Low • Nov 16New 90-day high: €3.58The company is up 27% from its price of €2.82 on 18 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Analyst Estimate Surprise Post Earnings • Nov 15Revenue in line with expectationsRevenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 1,828%, compared to a 2.8% growth forecast for the Pharmaceuticals industry in Germany.
공시 • Nov 05PLx Pharma Inc. to Report Q3, 2020 Results on Nov 13, 2020PLx Pharma Inc. announced that they will report Q3, 2020 results on Nov 13, 2020
공시 • Aug 07PLx Pharma Inc. to Report Q2, 2020 Results on Aug 14, 2020PLx Pharma Inc. announced that they will report Q2, 2020 results at 9:00 AM, Eastern Standard Time on Aug 14, 2020
공시 • Jul 02PLx Pharma Inc.(NasdaqCM:PLXP) dropped from Russell Microcap Value IndexPLx Pharma Inc.(NasdaqCM:PLXP) dropped from Russell Microcap Value Index